ErbB-2 Inhibitor ARRY-380

Known as: ONT-380 
An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2016-2018
01220162018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Tucatinib is a potent and selective oral HER2 tyrosine kinase inhibitor, with the potential to provide a well… (More)
Is this relevant?
2017
2017
Purpose: ONT-380 (ARRY-380) is a potent and selective oral HER2 inhibitor. This Phase I study determined the MTD… (More)
Is this relevant?
2016
2016
The clinical development of the HER2-specifi c monoclonal antibody trastuzumab is an oncology success story. Adding trastuzumab… (More)
Is this relevant?
Review
2016
Review
2016
The natural history of HER2-positive breast cancer has progressively improved since the introduction of the first anti-HER2… (More)
Is this relevant?